[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Geisinger Clinic\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":357},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,45,75,101,124,147,172,198,222,251,275,302,333],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100486774","enhancing-pap-adherence-among-spanish-speaking-hispanic-adults-with-osa-100486774",false,"NCT05618444","Enhancing PAP Adherence Among Spanish-speaking Hispanic Adults With OSA","Enhancing Positive Airway Pressure (PAP) Adherence Among Spanish-Speaking Hispanic Adults With Obstructive Sleep Apnea (OSA)","Inclusion Criteria:\n\n* Spanish-speaking and reading\n* Self-identified Hispanic\n* Adults ≥ 18 years-old\n* Males and females\n* Moderate-severe OSA defined as AHI ≥15 events\u002Fhour using a hypopnea criterion of a 4% oxygen desaturation (AHI4%)\n* Expected availability for the duration of the study (6 months from date of randomization)\n* Ownership of smartphone with unlimited text messaging capability\n* Referred to PAP treatment and able and willing to be treated with PAP\n\nExclusion Criteria:\n\n* Other sleep apnea or nocturnal respiratory insufficiency or failure diagnosis other than OSA established by polysomnogram (PSG) or home sleep apnea test (HSAT)\n* Requirement of supplemental oxygen or other non-invasive ventilation modality\n* Women referred to PAP because of new-onset OSA with pregnancy as PAP treatment may be time-limited (enrolled women who become pregnant during the trial and are already on PAP treatment will not be excluded)\n* Anticipated or scheduled bariatric surgery and\u002For referred to sleep evaluation by bariatric surgery","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study seeks to enhance long-term positive airway pressure (PAP) adherence among Spanish-speaking Hispanic adults, a group with known PAP outcomes disparities. This study will assess the feasibility of a linguistically and culturally adapted tele-management intervention (Automated Management, AM) for Spanish-speaking Hispanic adults with OSA.",[26],"Obstructive Sleep Apnea",[28,29,30,31],"positive airway pressure (PAP)","adherence","Hispanic","tele-management","NOT_YET_RECRUITING","2026-05-26",{"date":35,"type":36},"2026-05-28","ACTUAL",{"date":38,"type":20},"2026-09",{"date":40,"type":20},"2027-04",{"name":42,"class":43},"Geisinger Clinic","OTHER",4,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100639535","phase-2-the-effects-of-timolol-on-healing-and-cosmesis-of-mohs-scalp-wounds-an-open-label-trial-100639535","NCT07583862","The Effects of Timolol On Healing and Cosmesis of Mohs Scalp Wounds: An Open Label Trial","Inclusion Criteria:\n\nAge: Adults aged 18 years and older. Condition: Patients who have undergone Mohs surgery on the scalp. Consent: Ability to provide informed consent. Willingness to Participate: Willingness to comply with study procedures and attend follow-up visits.\n\nHealing by Secondary Intention: Wounds intended to heal by secondary intention.\n\nExclusion Criteria:\n\n* Known allergy or sensitivity to timolol or any components of the study medication.\n* Bronchial asthma or history of bronchial asthma\n* Severe chronic obstructive pulmonary disease (COPD)\n* Sinus bradycardia\n* Second or third-degree atrioventricular block\n* Overt heart failure\n* Cardiogenic shock\n* Under the influence of opioids or benzodiazepines at time of enrollment\n* History of scarring alopecia in area of Mohs wound\n* History of radiation treatment\n* Patients being treated for recurrent tumors",{"count":52,"type":20},40,[54],"PHASE2","The goal of this study clinical trial is to learn if topical timolol can accelerate healing and improve the cosmetic appearance of surgical wounds on the scalp following Mohs surgery. It will include Geisinger patients 18 year or older who undergo Mohs surgery of the scalp with planned wound healing by secondary intent. The main questions in aim to answer are:\n\n1. Compare wound healing speed between patients treated with topical timolol and those receiving standard wound care only.\n2. Compare cosmetic outcomes using topical timolol and standard wound care.\n3. Evaluate the impact of topical timolol on the number of unplanned follow-up visits and calls related to delayed wound healing.\n\nParticipants will be asked use either topical timolol or use standard wound care to treat their Mohs surgery scalp wound. They will follow-up around 4, 8 and 12 weeks.",[57,58],"Surgical Wounds","Mohs Surgery",[60,61,62,63,64,65],"Mohs surgery","wound healing","wound granulation","timolol","scar cosmesis","scars","2026-05-07",{"date":68,"type":36},"2026-05-13",{"date":70,"type":20},"2026-07-01",{"date":72,"type":20},"2029-03",{"name":42,"class":43},1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":92,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":74},"100626153","optimizing-referral-pathways-for-patients-with-hematuria-and-moderate-severe-proteinuria-100626153","NCT07431931","Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria","Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria - Phase 2: A Quality Improvement Project","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Patients receiving care from any Geisinger primary care provider (record of an encounter with a Geisinger PCP within the last 2 years from date of survey implementation)\n* Patients with high-risk glomerulonephritis features i.e. positive test results for hematuria (urine dipstick result with blood 1+ or greater) and proteinuria (2+ or 3+ protein on dipstick or ACR≥300 mg\u002Fg or PCR ≥500 mg\u002Fg) collected within 12 months of index date.\n\nExclusion Criteria:\n\n* Patients with a nephrologist appointment in the last 12 months before the index date\n* Patients with a prior appointment with a nephrologist within the last 2 years before the positive urinalysis test for hematuria (1+ or greater)\n* Patients with a history of glomerulonephritis and\u002For kidney failure (dialysis or eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m2, or kidney transplantation) at any time during the baseline\n* Patients receiving palliative care at any time during the baseline",{"count":83,"type":20},1200,[23],"The purpose of the study is to evaluate prospectively the impact of an electronic health record (EHR) alert on primary care providers' (PCP) referral to Nephrology of Geisinger patients with high risk signs (blood and protein in the urine) of glomerulonephritis. This will help quantify the relative effectiveness of EHR alerts on PCPs' referral patterns.",[87,88,89,90,91],"Referral and Consultation","Glomerulonephritis","Hematuria","Proteinuria","Kidney Disease",[93],"Hematuria; Proteinuria; Albuminuria; Glomerulonephritis; Clinical Decision Support; EHR Alert; Referral; Nephrology",{"date":95,"type":36},"2026-05-12",{"date":97,"type":20},"2026-11",{"date":99,"type":20},"2027-12",{"name":42,"class":43},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":4},"100589902","ndyag-vs-alexandrite-laser-treatment-in-hidradenitis-suppurativa-100589902","NCT06960447","Nd:YAG vs Alexandrite Laser Treatment in Hidradenitis Suppurativa","Comparative Efficacy of Nd:YAG and Alexandrite Laser Treatments in Hidradenitis Suppurativa: A Split-Person, Non-Inferiority Study","Inclusion Criteria:\n\n* Geisinger male or female patients with a diagnosis of hidradenitis suppurativa (all stages of disease)\n* 12-75 years of age\n* Not on concurrent systemic therapy (e.g., antibiotics, biologic therapies)\n* Must have not used systemic therapies within 2 weeks of enrollment in study\n* Able and willing to provide consent\n\nExclusion Criteria:\n\n* Patients who cannot tolerate laser therapy\n* Patients who cannot wear protective eyewear\n* Patients who are pregnant","12 Years","75 Years",{"count":111,"type":20},21,[23],"The purpose of this study is to evaluate whether Alexandrite laser treatment is non-inferior to Nd:YAG (neodymium-doped yttrium aluminum garnet) laser treatment of hidradenitis suppurativa (HS).",[115],"Hidradenitis Suppurativa (HS)","2026-04-24",{"date":118,"type":36},"2026-04-28",{"date":120,"type":20},"2026-07",{"date":122,"type":20},"2027-07",{"name":42,"class":43},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":133,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":74},"100607228","informing-low-acuity-emergency-department-patients-of-non-emergent-resources-2-100607228","NCT07185828","Informing Low-acuity Emergency Department Patients of Non-emergent Resources (2)","Informing Low-acuity Emergency Department Patients of Non-emergent Healthcare Resources Following Discharge to Decrease Emergency Department Utilization (2)","Inclusion Criteria:\n\n* \\>= 18 years of age\n* Geisinger ED visit rated as low acuity (L4 or L5)\n* Discharged from Geisinger ED in past 24 hours\n\nExclusion Criteria:\n\n* Cannot be contacted via the communication modality being used in the study (i.e., SMS), due to insufficient\u002Fmissing contact information in the EHR or because the patient opted out\n* Admitted to hospital\n* Already included in intervention in past 365 days",{"count":132,"type":20},8286,[23],"The goal of this campaign is to reduce unnecessary visits to a Geisinger emergency department (ED). In this campaign, patients will be assigned to receive or not receive outreach following ED discharge with a low-acuity visit designation. Outreach will occur via a text message the day after discharge from the ED as well as information added to the patient's after visit summary (AVS). Depending on the assigned condition, it will include calls to see their primary care provider (PCP) or use an Intelligent Triage tool. The study will assess whether ED use within the following 120 days differs across patients in different outreach conditions (current standard practice vs contact your PCP vs use Intelligent Triage). It will also examine whether patients follow through on the message-specific calls to action differently across conditions.",[136,137],"Emergency Service, Hospital","Behavior Change Interventions","RECRUITING","2026-03-12",{"date":141,"type":36},"2026-03-13",{"date":143,"type":36},"2025-04-15",{"date":145,"type":20},"2026-08",{"name":42,"class":43},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":21,"phases":157,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":74},"100608149","evaluation-of-a-peer-recovery-support-program-adapted-to-target-retention-in-clinic-based-medication-for-opioid-use-disorder-treatment-100608149","NCT07197801","Evaluation of a Peer Recovery Support Program Adapted to Target Retention in Clinic-based Medication for Opioid Use Disorder Treatment","PEERS","Inclusion Criteria:\n\n* Adult ≥ 18 years of age\n* Initiated medication for opioid use disorder treatment in past 45 days in a Geisinger outpatient clinic\n* Willing and able to give informed consent\n\nExclusion Criteria:\n\n* Received medication for opioid use disorder treatment at a Geisinger outpatient clinic in the 90-day period prior to the treatment initiation date\n* Not proficient in English","89 Years",{"count":156,"type":20},218,[23],"The goal of this clinical trial is to learn if receiving peer recovery support (support services provided by trained \"peers\" with lived experience of addiction and recovery) improves retention in medication treatment among people with opioid use disorder. The main question it aims to answer is: does peer recovery support improve retention in medication treatment for opioid use disorder?\n\nResearchers will compare two groups: (1) standard care combined with a peer recovery support program, and (2) standard care alone, to see if peer recovery support works to improve retention in medication treatment for opioid use disorder.\n\nParticipants will: visit clinics as they normally would to receive standard care (medication treatment for opioid use disorder); complete two questionnaires - one when they start treatment and one 6 months later; and agree to let researchers use information from their medical record. Participants in group 1 will also be invited to meet with a peer recovery support specialist for up to 6 months.",[160],"Opioid Use Disorder",[162,163],"Medication for opioid use disorder","Peer recovery support","2026-02-16",{"date":166,"type":36},"2026-02-18",{"date":168,"type":36},"2025-12-23",{"date":170,"type":20},"2029-07-31",{"name":42,"class":43},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":179,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":21,"phases":182,"briefSummary":183,"conditions":184,"keywords":188,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":74},"100595126","cmsl-ambulatory-sensitive-condition-nudge-study-2-100595126","NCT07028398","CMSL Ambulatory Sensitive Condition Nudge Study 2","Nurse Follow-up to Reduce Inappropriate Emergency Department Utilization in Adult Patients Seen for Ambulatory Sensitive Conditions in CMSL Study 2","Inclusion Criteria:\n\n* Age 30 years +\n* Has a qualifying visit in CMSL with an ambulatory sensitive condition (ASC) encounter diagnosis","30 Years",{"count":181,"type":20},12990,[23],"The project aims to evaluate a nurse-led intervention to reduce inappropriate emergency department (ED) use among adult patients seen at Geisinger's Community Medicine Service Line (CMSL) clinics. The intervention occurs immediately following an appointment where a patient receives a diagnosis of an ambulatory sensitive condition (ASC; i.e., a condition considered to be a risk factor for near-term ED use). The evaluation will compare eligible patients with an ASC who were randomly assigned to receive follow-up outreach (patient portal message and\u002For call) from a nurse (who was automatically prompted via the Epic electronic health record system to initiate outreach) with those who were randomly assigned to receive standard care. Analyses will be intent-to-treat. The primary outcome is ED use in the week (i.e., 7 days) following the appointment.\n\nWe ran an earlier version of this intervention (NCT06798389). The current study is modified based on results and clinical guidance. Specifically, more conditions will be included as qualifying ASCs for enrollment. Patients under 30 will be excluded. And rather than calling all patients as in the original study, patient portal users may be contacted via the portal instead of or in addition to a phone call. Finally, in the first study, the intervention was differentially effective by age group (\\\u003C45, 45-64, 65+). Our primary analysis will be conducted separately by age group, though we will also conduct an analysis combining across age groups.\n\nWe will run the study until we reach at least 4,330 patients in each of the following age groups: patients aged 30-45, patients aged 45-64, patients aged 65+. Therefore, our estimated sample size is at least 4,330x3 = 12,990.\n\nWe may be required to do an interim data pull and\u002For stop the study early at the direction of clinical or operational leaders.",[185,186,187],"Behavioral Intervention","Emergency Department Visits","Nurse Care Coordination",[189],"Nudge","2026-02-10",{"date":192,"type":36},"2026-02-11",{"date":194,"type":36},"2025-05-29",{"date":196,"type":20},"2026-07-31",{"name":42,"class":43},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":205,"sex":16,"minAge":206,"maxAge":108,"enrollmentInfo":207,"targetDuration":4,"studyType":21,"phases":209,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":74},"100428758","phase-4-clinical-and-radiographic-success-of-mta-vs-biodentine-100428758","NCT04863222","Clinical and Radiographic Success of MTA vs Biodentine","Clinical and Radiographic Success of Mineral Trioxide Aggregate (MTA) vs Septodont Biodentine in Primary Molars in Pulpotomy and Indirect Pulp Cap Treatments","Inclusion Criteria:\n\n* Male or female patients ages of 2 to ≤12 years.\n* Bilateral symptomatic or asymptomatic vital primary molars with caries approximating or into the pulp.\n* Patient who need a pulpotomy and\u002For indirect pulp cap treatments in two or more quadrants.\n* Parents of patients who can provide consent in English.\n* Patients who need treatment in an operating room setting at Geisinger.\n\nExclusion Criteria:\n\n* Pre-operative radiographic or clinical symptoms associated with irreversible pulpitis or necrotic pulp.\n* Radiographs not displaying furcation region of the tooth.\n* Patients with cardiac conditions who need prophylaxis for infective Endocarditis.\n* Patients with any type of cancer in the past or present.\n* Non-restorable molars.",true,"2 Years",{"count":208,"type":20},646,[210],"PHASE4","The purpose of this prospective study is to compare the clinical and radiographic success of MTA and Biodentine as a medicament in vital pulp therapy in maxillary and mandibular primary molars in a pediatric population. There is limited research currently on Biodentine since it's a novel product. Biodentine is less expensive than MTA and does not cause discoloration like MTA. Biodentine may be an alternative medicament used for vital pulp therapy in primary molars.",[213,214],"Indirect Pulp Cap","Pulpotomy","2025-12-22",{"date":168,"type":36},{"date":218,"type":36},"2021-11-12",{"date":220,"type":20},"2026-12-01",{"name":42,"class":43},{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":231,"phases":4,"briefSummary":232,"conditions":233,"keywords":238,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":74},"100505546","liposomal-bupivacaine-and-transoral-robotic-surgery-100505546","NCT05862792","Liposomal Bupivacaine and Transoral Robotic Surgery","Impact of Liposomal Bupivacaine on Post-operative Pain, Opioid Use, and Swallow Function in Transoral Robotic Surgery","Inclusion Criteria:\n\n* Adult patients, greater than or equal to 18 years of age; Patients of all genders; Patients undergoing transoral robotic surgery; Patient who are able and willing to give consent\n\nExclusion Criteria:\n\n* Patients with an allergy to Bupivacaine or other amide anesthetics; Patients with a carnitine deficiency",{"count":230,"type":20},80,"OBSERVATIONAL","This study is for patients with oropharyngeal squamous cell carcinoma. We want to learn more about how we can optimize pain control in patients who undergo transoral robotic surgery (TORS) for oropharyngeal squamous cell carcinoma. Our goal is to determine if a local anesthetic called EXPAREL® (Liposomal Bupivacaine) impacts postsurgical pain and swallow function in patients with oropharyngeal squamous cell carcinoma undergoing TORS. EXPAREL® is an FDA-approved anesthetic drug that provides long-lasting and precise pain relief when injected into the surgical wound. Our study team wants to determine if injecting EXPAREL® into the surgical wound will provide better pain relief and swallow function when compared to patients who do not undergo postoperative EXPAREL® injection. Both options for postoperative pain control are considered standard of care for patients undergoing TORS.",[234,235,236,237],"Oropharyngeal Cancer","Dysphagia, Oropharyngeal","Post Operative Pain","Transoral Robotic Surgery",[239,240,241,242],"oropharyngeal cancer","squamous cell carcinoma","postoperative pain","transoral robotic surgery","2025-09-05",{"date":245,"type":36},"2025-09-09",{"date":247,"type":36},"2023-06-01",{"date":249,"type":20},"2026-01-15",{"name":42,"class":43},{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":21,"phases":261,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":274},"100474954","early-phase-1-geisinger-antibiotic-allergy-pilot-program-assess-and-address-100474954","NCT05464615","Geisinger Antibiotic Allergy Pilot Program: Assess and Address","Geisinger Antibiotic Allergy Pilot Program: Assess and Address (GAAP) Penicillin Allergy De-labeling in Inpatient Setting by Performing Direct Oral Amoxicillin Challenge in Low-risk Patients","GAAP","Inclusion Criteria:\n\n* Hospitalized male or female patients with a history of Penicillin (PCN) allergy or PCN-derivative allergy as reported by patient or documented in Epic\n* ≥18 years of age\n* Patients with a medical need for treatment with a PCN or PCN-derivative or other beta-lactam antibiotics as determined by an inpatient provider\n* Able and willing to provide consent in English.\n\nExclusion Criteria:\n\n* History of documented immediate-onset severe allergic reaction or delayed onset hypersensitivity reaction to a PCN or PCN-derivative\n* Patients who are hemodynamically unstable (e.g., pulse oximetry O2 saturation \\\u003C90 %, respiratory rate \\>=21 per minute, severe hypoxia requiring non-invasive ventilation, high-flow nasal canula, or mechanical ventilation, refractory hypotension requiring vasopressor support, heart rate \\>100 beats per minute, etc.)\n* Patients with uncontrolled pulmonary diseases (like exacerbation of asthma, Chronic Obstructive Pulmonary Disease (COPD), and\u002For other forms of chronic lung diseases)",{"count":260,"type":20},100,[262],"EARLY_PHASE1","This is a prospective non-inferiority study to evaluate penicillin allergy history in patients with reported penicillin allergy, who require penicillin or penicillin-derivative antibiotic during inpatient admission using a focused questionnaire. A simplified scoring system will be assigned to patient responses, and the total score will be utilized to identify low-risk patients that have a minimal risk of allergic reactions on exposure to penicillin or its derivative. Patients determined to have low risk based on this questionnaire will be offered a test dose (graded challenge) of amoxicillin in a supervised setting, and if they tolerate it, penicillin allergy label will be removed from patient's chart. We hypothesize that at least 95% of low-risk patients will successfully pass the graded amoxicillin challenge so the penicillin allergy label can be removed from their charts. A proportion as low as 0.85 would be a good clinical outcome and considered non-inferior to the expected proportion of 0.95.",[265],"Penicillin Allergy","2025-08-18",{"date":268,"type":36},"2025-08-22",{"date":270,"type":36},"2024-03-04",{"date":272,"type":20},"2025-12-31",{"name":42,"class":43},3,{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":21,"phases":284,"briefSummary":285,"conditions":286,"keywords":290,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":4},"100588078","phase-4-perioperative-colchicine-for-tka-100588078","NCT06936709","Perioperative Colchicine for TKA","Effect of Colchicine in the Perioperative Period on Reducing Post-Operative Pain in Total Knee Arthroplasty","Inclusion Criteria:\n\n* Patients 18 years or older undergoing elective total knee arthroplasty for osteoarthritis.\n\nExclusion Criteria:\n\n* Subject has impaired hepatic function (Child-Pugh Class \\>B)\n* Subject has impaired renal function (GFR \\\u003C 60 ml\u002Fmin\u002F1.73 m2)\n* Subject has known adverse reaction to colchicine\n* Subject has chronic opioid use (Filled opioid medication twice within 6 months of surgical date)\n* Subject is pregnant or expecting to become pregnant during the time of the study associated with colchicine exposure (postoperative days 0-3)\n* Subject is unable to provide informed consent\n* Subject is actively prescribed medication that interact with colchicine in a manner that would increase the risk of colchicine toxicity, i.e.:\n* Antifungals: Ketoconazole, itraconazole, fluconazole, etc…\n* Macrolides : Clarithromycin, erythromycin\n* HIV protease : Ritonavir, Atazanavir, saquinavir, etc...\n* Ca2+: Verapamil and Diltiazem\n* Cyclosporine\n* Danazol\n* Amiodorone\n* Quinidine\n* Anti-hepaciviral combinations\n* Grapefruit juice\n* Statins: atorvastatin, lovastatin, simvastatin, etc…\n* Gemfibrozil and other fibrates\n* Digoxin",{"count":283,"type":20},75,[210],"This study is a prospective, randomized, double-blinded, placebo-controlled study of the drug colchicine in the acute postoperative period for patients who are undergoing a total knee arthroplasty (TKA). Patients aged 18 years or older who are undergoing TKA will be invited to participate in the study. The primary endpoint of this study is to determine if colchicine, an anti-inflammatory medication commonly used for gout attacks, will decrease the postoperative pain of patients undergoing elective TKA.",[287,288,289],"Osteoarthritis of Knee","Recovery Following Primary Total Knee Arthroplasty","Perioperative Pain Control",[291,292,293],"Total Knee Arthroplasty","Colchicine","Postoperative Pain","2025-08-15",{"date":296,"type":36},"2025-08-17",{"date":298,"type":20},"2025-12-01",{"date":300,"type":20},"2026-03-01",{"name":42,"class":43},{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":16,"minAge":309,"maxAge":310,"enrollmentInfo":311,"targetDuration":4,"studyType":21,"phases":313,"briefSummary":314,"conditions":315,"keywords":321,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":74},"100554125","how-omt-benefits-newly-diagnosed-patients-with-respiratory-illness-when-given-alongside-other-standard-care-100554125","NCT06495021","How OMT Benefits Newly Diagnosed Patients With Respiratory Illness When Given Alongside Other Standard Care.","OMT and Respiratory Illness","Inclusion Criteria:\n\n* Patients being seen for respiratory illness symptoms at Geisinger 65-Forward Buckhorn, PA clinic for care.\n* Patients age of 65-100\n* New diagnosis of upper respiratory illness, sinusitis, bronchitis, or pneumonia during outpatient visit.\n\nExclusion Criteria:\n\n* Patients that have a healing fracture, including the spine, pelvis, shoulder, ribs, vertebrae, or extremities.\n* Patients actively receiving any type of cancer treatment\n* Patients with active or previously diagnosed liver disease.","65 Years","100 Years",{"count":312,"type":20},68,[23],"This study is to see Osteopathic Manipulative Therapy, or OMT, can aid in treating patients being seen for respiratory illness and associated symptoms. The hypothesis is that the addition of OMT therapy, alongside other standard care (such as a medication), can help lessen patient symptoms sooner than just other treatment alone, and the duration of the condition will shorten as well.",[316,317,318,319,320],"Pneumonia","Sinusitis","Bronchitis","Respiratory Disease","Respiratory Tract Infections",[322,323,324],"Osteopathic Manual Therapy","Respiratory Illness","OMT","2025-07-07",{"date":327,"type":36},"2025-07-08",{"date":329,"type":36},"2024-12-31",{"date":331,"type":20},"2026-06",{"name":42,"class":43},{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":11,"sex":16,"minAge":340,"maxAge":341,"enrollmentInfo":342,"targetDuration":4,"studyType":21,"phases":344,"briefSummary":345,"conditions":346,"keywords":4,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":356},"100418764","biomechanical-footwear-as-a-non-invasive-alternative-and-supplement-to-total-knee-replacement-100418764","NCT04732962","Biomechanical Footwear as a Non-invasive Alternative and Supplement to Total Knee Replacement","The Effect of a Biomechanical Footwear as a Non-invasive Alternative to Total Knee Replacement and as an Additional Rehabilitation Regimen Postoperatively","Inclusion Criteria:\n\n* Men or non-pregnant women\n* Between ages 45 and 80, inclusive\n* ACR clinical criteria for OA of the knee\n* Symptomatic uni- or bilateral OA of the knee for at least six months\n* Radiological criteria: X-rays showing tibiofemoral knee osteoarthritis defined as at least Kellgren and Lawrence Grade 2\n* At least a moderate NPRS pain score at baseline (≥5)\n* Score of 1-3 based on the American Society of Anesthesiologists Physical Status Classification System\n* Willing and able to read, comprehend, and sign the study informed consent form in English prior to study specific procedure\n\nExclusion Criteria:\n\n* Body Mass Index (BMI) \\> 40\n* History of an inflammatory rheumatic disease\n* Non-knee musculoskeletal pain that is more severe than the knee pain\n* Corticosteroids injections in the knees in the previous 6 weeks\n* Previous major surgery to the knee such as osteotomy, hemiprosthesis, unilateral total joint replacement excluding knee arthroscopy \\> 6 months\n* Patients with Geisinger Health Plan insurance for whom Apos is a covered treatment\n* Patients with a recent history (\\\u003C3 months) of a mental health condition, such as depression or anxiety\n* Problems with balance (\\>2 unexplained falls within the last 12 months; experiencing regular dizziness that has caused a trip or fall; using a walking aid to get around such as a rollator, cane, walker)","45 Years","80 Years",{"count":343,"type":20},150,[23],"Osteoarthritis (OA), the most common type of arthritis, affects more than 32.5 million adults in the United States. It is also among the most expensive condition to treat when joint replacement surgery is required. Although biomechanics plays an important role in OA disease, the non-surgical treatment options addressing biomechanics are scarce with limited effect. AposHealth is the fist biomechanical treatment that was shown to have a significant short-term effect on patients with knee OA.\n\nThe main objectives of this study are:\n\n1. To assess AposHealth, a non-invasive home-based biomechanical treatment, as an alternative treatment for patients who are eligible for Total Knee Replacement (TKR).\n2. To assess AposHealth as a new post-operative rehabilitation tool for patients post TKR.",[347],"Osteoarthritis, Knee","2025-04-28",{"date":350,"type":36},"2025-04-30",{"date":352,"type":36},"2021-07-22",{"date":354,"type":20},"2026-03",{"name":42,"class":43},2,""]